This trial is testing a new drug to see if it is safe and how well it works against different types of cancer.
6 Primary · 7 Secondary · Reporting Duration: From baseline and every 8 weeks through disease progression or study completion (approximately 2 years)
240 Total Participants · 9 Treatment Groups
Primary Treatment: PF-07104091 monotherapy dose expansion (ovarian) · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: